文献速递妇科产科

晚期卵巢癌初次减灭术1-10mm残留与间歇减灭术无肉眼残留的生存比较

Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
PubMed 文献 · Gynecol Oncol · 2020-01-15

该回顾性研究纳入2010至2016年FIGO IIIC-IV期上皮性卵巢/输卵管/原发腹膜癌患者207例,比较初次减灭术(PDS)后1-10mm残留(59例)与间歇减灭术(IDS)后无肉眼残留(148例)的生存与并发症。两组进展/复发率相近,中位PFS无显著差异(16.2 vs 18.9个月,p=0.111),但PDS组中位OS更短(41.4 vs 52.4个月,p=0.022)且围手术期并发症更高。结论支持若预计PDS会留下毫米级残留,应优先选择IDS。

要点

  • PDS组术中并发症16.9%、早期主要术后并发症28.8%,均显著高于IDS组的1.3%和2.0%。
  • 两组中位PFS无显著差异(16.2 vs 18.9个月,p=0.111),但PDS组中位OS更短(41.4 vs 52.4个月,p=0.022)。
  • 若预计PDS会留下1-10mm残留,IDS应作为首选治疗。

核心结论

  • 在晚期上皮性卵巢癌中,PDS后1-10mm残留与IDS后无肉眼残留相比,PFS相似但OS更短且围手术期并发症更多,IDS应优先考虑。

研究设计与样本

  • 回顾性纳入2010年1月至2016年12月FIGO IIIC-IV期上皮性卵巢/输卵管/原发腹膜癌患者207例,PDS组59例(残留1-10mm),IDS组148例(无肉眼残留),随访至少2年。

主要发现

  • PDS组患者更年轻且手术复杂度评分更高。
  • PDS组术中并发症发生率为16.9%,IDS组为1.3%;PDS组早期主要术后并发症发生率为28.8%,IDS组为2.0%(p<0.0001)。
  • 中位随访56.4个月(范围59.2-65.4),全人群117例(56.5%)死于疾病;PDS组48例(81.4%)进展/复发,IDS组120例(81.1%)进展/复发。
  • PDS组与IDS组中位PFS分别为16.2个月和18.9个月(p=0.111),中位OS分别为41.4个月和52.4个月(p=0.022)。

临床怎么用

  • 对于预计PDS难以达到无肉眼残留、可能遗留1-10mm残留的晚期卵巢癌患者,应优先选择IDS以降低围手术期并发症并可能改善总生存。

局限性

  • 本研究为回顾性设计,PDS组与IDS组在年龄和手术复杂度评分上存在差异,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare survival outcomes and peri-operative complications in patients with advanced ovarian cancer with 1-10 mm residual disease (RD) at primary debulking surgery (PDS) versus those achieving no gross residual disease (NGR) at interval debulking surgery (IDS). METHODS: Patients operated with the intent of complete cytoreduction for epithelial ovarian/fallopian tube/primary peritoneal cancer, FIGO stage IIIC-IV, RD 1-10 mm at PDS and NGR at IDS, between 01/2010 and 12/2016, were retrospectively included. All patients had at least 2-years of follow-up completed. RESULTS: 207 patients were included (59 PDS and 148 IDS). Patients in PDS group were younger and had a higher surgical complexity score. There was a higher rate of intra- and major early post-operative complications in the group of PDS vs IDS (16.9% vs 1.3% and 28.8% vs 2.0%, p < 0.0001 respectively). After a median follow up of 56.4 months (range 59.2-65.4), 117 (56.5%) patients died of disease in the whole population. Forty-eight (81.4%) patients had progression/recurrent disease in the PDS group and 120 (81.1%) in the IDS group. Median PFS was 16.2 months and 18.9 months for PDS and IDS group, respectively (p = 0.111). Median OS was 41.4 months and 52.4 months for PDS and IDS group, respectively (p = 0.022). CONCLUSIONS: IDS should be considered the preferred treatment in case millimetric residual disease is expected at PDS in view of the superimposable PFS and the reduced number of perioperative complications.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ghirardi V, Moruzzi MC, Bizzarri N, et al. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis. Gynecol Oncol. 2020. PMID: 31952843. doi:10.1016/j.ygyno.2020.01.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。